What question did this study set out to answer?

To assess whether integrating clinical-risk stratification with the 21-gene recurrence score improves prognostic accuracy and therapeutic decision-making for adjuvant breast cancer treatment.

June 3, 2019New England Journal of MedicineOpen Access

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

JSJoseph A. SparanoTisch Cancer Institute RGRobert J. GrayAmerican College of Radiology PRPeter M. RavdinThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Randomized trial reveals clinical risk combined with genomic scoring guides adjuvant therapy in premenopausal breast cancer, indicating pathways to optimize treatment.

Key Points

To assess whether integrating clinical-risk stratification with the 21-gene recurrence score improves prognostic accuracy and therapeutic decision-making for adjuvant breast cancer treatment.
Conducted a randomized clinical trial (ClinicalTrials.gov number, NCT00310180) evaluating adjuvant therapy assignment in breast cancer.
Combined clinical-risk stratification with 21-gene recurrence score results to evaluate prognosis and predict adjuvant therapy benefit.
Clinical-risk stratification provided prognostic information incremental to the 21-gene recurrence score.
The combination of clinical and genomic risk identified premenopausal women who derived benefit from more effective, intensive adjuvant therapy.

Cite This Study

Sparano et al. (2019) studied this question.

synapsesocial.com/papers/69de72297ed287395e558d68 https://doi.org/10.1056/nejmoa1904819

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals clinical risk combined with genomic scoring guides adjuvant therapy in premenopausal breast cancer, indicating pathways to optimize treatment.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider